We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · December 28, 2019

Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti–PD-1 Therapy in NSCLC

Journal of Thoracic Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-Programmed Cell Death-1 Therapy in NSCLC
J Thorac Oncol 2019 Dec 01;14(12)2071-2083, Y Ohue, K Kurose, T Karasaki, M Isobe, T Yamaoka, J Futami, I Irei, T Masuda, M Fukuda, A Kinoshita, H Matsushita, K Shimizu, M Nakata, N Hattori, H Yamaguchi, M Fukuda, R Nozawa, K Kakimi, M Oka

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading